TARIFFS LATEST

US, China to slash tariffs for 90 days

Vienna - Delayed Quote EUR

Recordati Industria Chimica e Farmaceutica S.p.A. (REC.VI)

51.25

-1.35

(-2.57%)

As of 3:30:45 PM GMT+2. Market Open.

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for REC.VI

Recordati SpA (RCDTF) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION

3 European Stocks Estimated To Be Trading At Discounts Of Up To 40.1%

3 European Stocks Estimated To Be Trading At Discounts Of Up To 40.1%

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

3 European Stocks Estimated To Be Undervalued In March 2025

3 European Stocks Estimated To Be Undervalued In March 2025

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

3 Companies That May Be Trading Below Their Estimated Value

3 Companies That May Be Trading Below Their Estimated Value

Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

Recordati SpA (RICFY) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

SNW.BE Sanofi SA

87.31

-5.56%

SNW.SG Sanofi SA

90.21

+1.92%

SNW2.MU Sanofi SA

44.00

-4.35%

0O59.IL Sanofi

90.24

-2.72%

SNW.HA Sanofi SA

88.30

-4.78%

AZNl.XC

1SAN.MI Sanofi

90.32

-3.23%

RHO5.HM Roche Holding AG

271.00

-1.53%

SNW.F Sanofi

90.29

-2.90%

AZNCF AstraZeneca PLC

127.45

-6.90%